Suchen
10X Genomics Inc
TXGZur Watchlist hinzufügen
35.730USD
+1.130+3.27%
Handelsschluss 06/25, 16:00（ET）Kurse um 15 Minuten verzögert
4.54BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 10X Genomics Inc Unternehmen
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
10X Genomics Inc Informationen
BörsenkürzelTXG
Name des Unternehmens10X Genomics Inc
IPO-datumSep 12, 2019
CEOSaxonov (Serge Wilson)
Anzahl der mitarbeiter1306
WertpapierartOrdinary Share
GeschäftsjahresendeSep 12
Addresse6230 Stoneridge Mall Road
StadtPLEASANTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94588
Telefon19254017300
Websitehttps://www.10xgenomics.com/
BörsenkürzelTXG
IPO-datumSep 12, 2019
CEOSaxonov (Serge Wilson)
Führungskräfte von 10X Genomics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.13M
-2.55%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
378.44K
+2.33%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+22.53%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
105.23K
-11.02%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
68.28K
+12.93%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
37.45K
+23.58%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
37.45K
+23.58%
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.13M
-2.55%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
378.44K
+2.33%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+22.53%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
105.23K
-11.02%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
68.28K
+12.93%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
37.45K
+23.58%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von 10X Genomics Inc?
Die fünf größten Anteilseigner von 10X Genomics Inc sind: Mr. Serge Wilson Saxonov, Ph.D.
Wie viele Institutionen halten Anteile an 10X Genomics Inc (TXG)?
Mit Stand vom 2026Q1 halten 726 Institutionen Anteile an 10X Genomics Inc, mit einem Gesamtmarktwert von etwa 140.84M, was 118.45% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2946322.00 gestiegen.
Was ist die größte Einnahmequelle von 10X Genomics Inc?
Am 2026Q1 erzielte das Geschäft mit Consumables für 10X Genomics Inc den höchsten Umsatz in Höhe von 507.18M, was 78.90% des Gesamtumsatzes entspricht.
